Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Qualigen Therapeutics ( (QLGN) ) just unveiled an update.
On January 28, 2025, Qualigen Therapeutics announced its participation as the first investor in the 2025 bridge funding round for NanoSynex, which aims to raise up to $500,000. This investment supports the development of NanoSynex’s Antimicrobial Susceptibility Testing technology, which is expected to significantly enhance diagnostic speed and accuracy, potentially expanding the market to $4.7 billion by 2027. NanoSynex plans to enter the EU and US markets by 2027 and 2028, respectively, with a promising pipeline and four patents protecting its technology.
More about Qualigen Therapeutics
Qualigen Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapeutic products and diagnostics. The company is committed to advancing innovative solutions for healthcare challenges, with a market focus on the rapid and accurate testing of antimicrobial susceptibility.
YTD Price Performance: -5.50%
Average Trading Volume: 57,193
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.13M
Find detailed analytics on QLGN stock on TipRanks’ Stock Analysis page.
